The fatty acid desaturase 1 (FADS1) antibody is a crucial tool for studying the FADS1 enzyme, a key regulator of polyunsaturated fatty acid (PUFA) metabolism. Encoded by the FADS1 gene, this enzyme catalyzes the introduction of double bonds in fatty acids, particularly converting dihomo-γ-linolenic acid (DGLA) to arachidonic acid (AA) and eicosatetraenoic acid to eicosapentaenoic acid (EPA). FADS1 is highly expressed in liver, brain, and adipose tissues, and its activity influences inflammatory responses, lipid homeostasis, and membrane fluidity. Genetic variations in FADS1 are linked to cardiovascular diseases, metabolic syndromes, and neurodevelopmental disorders. Researchers use FADS1 antibodies (monoclonal or polyclonal) to detect protein expression levels, cellular localization (e.g., endoplasmic reticulum), and regulatory mechanisms in tissues or cell lines via techniques like Western blot, immunohistochemistry (IHC), or immunofluorescence (IF). These antibodies also aid in exploring FADS1’s role in diseases, dietary interventions, or genetic knockout models. However, variability in antibody specificity across commercial sources may lead to inconsistent results, emphasizing the need for validation using positive controls or gene-edited cells. Overall, FADS1 antibodies are indispensable for unraveling lipid metabolism pathways and their implications in health and disease.